文献类型：期刊文献

英文题名：Temperature-sensitive copolymer-coated fluorescent mesoporous silica nanoparticles as a reactive oxygen species activated drug delivery system

作者：Yu, Feng[1];Wu, Huijing[1];Tang, Yao[1];Xu, Yufang[1];Qian, Xuhong[1];Zhu, Weiping[1]

机构：[1]East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab Chem Biol, State Key Lab Bioreactor Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China

年份：2018

卷号：536

期号：1

起止页码：11

外文期刊名：INTERNATIONAL JOURNAL OF PHARMACEUTICS

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000424259100002)】；

基金：This work was supported by the National Natural Science Foundation of China (Grants 21476077, 21236002) and Shanghai Pujiang Program. W. Zhu is grateful for the support from Chinese Scholarship Council.

语种：英文

外文关键词：Mesoporous silica nanoparticles; Stimuli-responsive system; Controlled delivery system; Reactive oxygen species

摘要：In this study, a temperature and ROS-responsive drug delivery system ROSP@MSN based on mesoporous silica nanoparticles has been designed and synthesized by taking advantage of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzyl acrylate modified polymers (ROSP) as "nano-valve", which can respond selectively to cancer exclusive microenvironment and implement targeted drug release. Due to the superior temperature-sensitive properties of ROSP, ROSP@MSN could achieve cargo loading in cold water, and subsequently close the pore by raising temperature to obtain ROSP@MSN@DOX. Upon the stimulus of ROS, ROSP@MSN@DOX shows good release performance at physiological conditions. The cytotoxicity study demonstrates that the cell viability is about 80% after Hela cells are treated with ROSP@MSN at a concentration of 100 mu g/mL for 24 h, exhibiting the good biocompatibility of ROSP@MSN. Furthermore, after treated with ROSP@MSN@DOX at a concentration of 100 mu g/mL for 24 h, the viability of Hela cells is reduced to 40.5%; Control experiments demonstrate that, when Hela cells are pretreated with active oxygen scavenger, cell viability is about 65.3% due to the significant decrease of intracellular reactive oxygen species. Therefore, the therapeutic nanocarrier with effective encapsulation and release capacity in particular situation is a great candidate for the new drug delivery platform for targeted cancer therapy.